Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Terminated 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gynecologic 14Genitourinary 5Breast 5Thoracic 2Gastrointestinal 2Sarcoma 1Plasma cell 1Other hematologic neoplasm 1Myeloid 1Lymphoid 1CNS 1

Conditions

Carcinoma, Non-Small-Cell Lung 3Small Cell Lung Carcinoma 2Prostatic Neoplasms 2Pancreatic Neoplasms 2Ovarian Neoplasms 2Lung Neoplasms 2Colorectal Neoplasms 2Breast Neoplasms 2Uterine Cervical Neoplasms 1Urinary Bladder Neoplasms 1Stomach Neoplasms 1Sarcoma 1Primary Myelofibrosis 1Neoplasm Metastasis 1Myeloproliferative Disorders 1Myelodysplastic Syndromes 1Multiple Myeloma 1Mesothelioma, Malignant 1Lymphoma, Non-Hodgkin 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma 1Leukemia 1Leiomyosarcoma 1Glioblastoma 1Fallopian Tube Neoplasms 1Esophageal Neoplasms 1Endometrial Neoplasms 1Colonic Neoplasms 1Carcinosarcoma 1Adenocarcinoma of Lung 1

Interventions

pembrolizumab 42Carboplatin 24Cyclophosphamide 20Paclitaxel 19Nivolumab 17Cisplatin 15fludarabine 14Gemcitabine 12aldesleukin 10Docetaxel 10Bevacizumab 9Magnetic Resonance Spectroscopy 8Trastuzumab 7Specimen Handling 7Drug Therapy 7Pemetrexed 6Oxaliplatin 6Ipilimumab 6Interleukin-2 6Fluorouracil 6Cetuximab 6Blood Specimen Collection 6sargramostim 5pegfilgrastim 5avelumab 5Topotecan 5Taxes 5Irinotecan 5palbociclib 4durvalumab 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Ovarian Neoplasms × rucaparib × Thoracic × Clear all
NCT02711137 2025-10-21

Open-Label Safety and Tolerability Study of INCB057643 in Subjects With Advanced Malignancies

Incyte Corporation

Phase 1/2 Terminated
137 enrolled 31 charts
BreastCNSGastrointestinalGenitourinaryGynecologicLymphoidMyeloidOther hematologic neoplasmPlasma cellThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Glioblastoma, Leukemia, Lymphoma, Lymphoma, Non-Hodgkin, Multiple Myeloma, Myelodysplastic Syndromes, Myeloproliferative Disorders, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Colorectal Neoplasms, Lymphoma, Large B-Cell, Diffuse, Primary Myelofibrosis

NCT04171700 2023-10-02

LODESTAR

pharmaand GmbH

Phase 2 Terminated
83 enrolled 16 charts
BreastGastrointestinalGenitourinaryGynecologicSarcomaThoracic

Urinary Bladder Neoplasms, Breast Neoplasms, Carcinosarcoma, Uterine Cervical Neoplasms, Colonic Neoplasms, Esophageal Neoplasms, Fallopian Tube Neoplasms, Leiomyosarcoma, Lung Neoplasms, Neoplasm Metastasis, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Sarcoma, Stomach Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡